Comparative study of several hypolipidemic agents related to clofibrate.
D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use; D001713:Biphenyl Compounds; D001796:Blood Protein Disorders / Q000097:blood / Q000188:drug therapy*; D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic; D002994:Clofibrate / Q000627:therapeutic use*; D004357:Drug Synergism; D004987:Ethers / Q000627:therapeutic use; D005227:Fatty Acids / Q000627:therapeutic use*; D005260:Female; D006218:Halofenate / Q000627:therapeutic use*; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy; D006949:Hyperlipidemias / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D050356:Lipid Metabolism; D008074:Lipoproteins / Q000097:blood*; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D009255:Nafenopin / Q000627:therapeutic use*; D010919:Placebos; D014280:Triglycerides / Q000097:blood; D014527:Uric Acid / Q000097:blood / Q000378:metabolism; D014801:Vitamin A; D014812:Vitamin K / Q000378:metabolism
D000925:Anticoagulants; D001713:Biphenyl Compounds; D004987:Ethers; D005227:Fatty Acids; D000960:Hypolipidemic Agents; D008074:Lipoproteins; D008077:Lipoproteins, LDL; D010919:Placebos; D014280:Triglycerides; D009255:Nafenopin; D014801:Vitamin A; D014812:Vitamin K; D014527:Uric Acid; D002784:Cholesterol; D002994:Clofibrate; D006218:Halofenate